Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) Director Staffan Encrantz acquired 126,664 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was purchased at an average price of $2.19 per share, for a total transaction of $277,394.16. Following the acquisition, the director now directly owns 157,499 shares in the company, valued at approximately $344,922.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Staffan Encrantz also recently made the following trade(s):
- On Tuesday, November 14th, Staffan Encrantz bought 3,462 shares of Sight Sciences stock. The stock was purchased at an average cost of $2.00 per share, with a total value of $6,924.00.
Sight Sciences Price Performance
Sight Sciences stock opened at $2.28 on Tuesday. The company has a current ratio of 12.11, a quick ratio of 11.47 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $6.28. The stock has a market cap of $111.15 million, a P/E ratio of -1.80 and a beta of 1.52. Sight Sciences, Inc. has a 12-month low of $1.04 and a 12-month high of $15.30.
Analyst Upgrades and Downgrades
Institutional Trading of Sight Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of SGHT. Mine & Arao Wealth Creation & Management LLC. acquired a new position in shares of Sight Sciences during the 1st quarter worth about $33,000. Cubist Systematic Strategies LLC purchased a new stake in Sight Sciences during the third quarter worth approximately $37,000. FMR LLC boosted its holdings in Sight Sciences by 484.6% in the second quarter. FMR LLC now owns 4,864 shares of the company’s stock valued at $44,000 after purchasing an additional 4,032 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Sight Sciences in the fourth quarter valued at approximately $54,000. Finally, Citigroup Inc. raised its holdings in Sight Sciences by 363.9% during the second quarter. Citigroup Inc. now owns 7,942 shares of the company’s stock worth $66,000 after purchasing an additional 6,230 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors and hedge funds.
About Sight Sciences
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.
- Five stocks we like better than Sight Sciences
- How to Calculate Stock Profit
- The most upgraded stocks in November have two things in common
- How to Invest in Solar Energy
- Monday.com rocked earnings like it’s the weekend
- The How And Why of Investing in Oil Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.